Recruitment is where trials die. Here is how HelixChain is designed to take a hidden, un-poolable population to an enrolled cohort — every step scored, matched, and provable. This journey draws on AI and Blockchain; CRISPR comes later. The figures below are an illustrative walkthrough.
Across six partner institutions, 12,480 patients carry the indication. Their genomes can't be centralised — so the AI queries them where they live and moves no data.
The AI narrows to the exact genotype the therapy targets. 12,480 becomes 1,940 — the only patients the edit can actually help.
Inclusion and exclusion rules — age, prior therapy, organ function — are applied automatically. 1,940 becomes 310.
The AI ranks by clinical fit and proximity to a qualified treatment centre. 310 becomes 84, distributed across five centres that can treat them.
Candidates are approached, and granular consent is written to the blockchain ledger — tamper-evident from the very first signature. 84 approached, 41 consented.
Consented patients are enrolled and pseudonymised, and every eligibility decision is written to an immutable provenance trail. 38 enrolled against a target of 36.
Recruit in weeks, not months — from a population you couldn't reach before.
Site-matched, protocol-eligible, and ready to consent.
Identified while the therapy can still help them.
Every include and exclude decision, logged and inspectable.
We're building the Governance Foundation with a small group of treatment centres and sponsors. Design partners see journeys like this on their own trials first.